Conversely, population studies have found no association between increased risk of diabetic retinopathy and GLP-1 RA use [104, 105], with a low odds ratio observed for exenatide (OR 0.16), liraglutide (OR 0.18), albiglutide (OR 0.09), and dulaglutide (OR 0.11) [106]
Limited RCTs have been published thus far on patient populations with hypertension specifically, with blood pressure variations being measured as a primary endpoint and tracked long-term
Patients should confirm ingredient form, dosing units, and pharmacy legitimacy with the prescribing clinician and dispensing pharmacy
Check if your Anthem Blue Cross Blue Shield plan may cover weight loss treatment in Arizona Find the right provider for your needs select your state to find expert care near you.
The company aims to file in early 2026 for a potential 2026 approval